Why Is Blood Cancer-Focused Shattuck Labs Stock Soaring Today?
Portfolio Pulse from Vandana Singh
Shattuck Labs Inc (NASDAQ:STTK) reported positive initial data from a Phase 1A/B trial of SL-172154 in combination with Azacitidine for treating high-risk myelodysplastic syndromes (HR-MDS) and TP53 mutant acute myeloid leukemia (AML) patients. The study showed a 79% Objective Response Rate in HR-MDS patients and a 27% initial complete response rate in TP53m AML patients. The safety profile was acceptable, and the stock price soared by 91.3% to $4.03.
December 13, 2023 | 2:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Shattuck Labs Inc's stock surged due to positive trial results for its SL-172154 treatment, showing high response rates in HR-MDS and TP53m AML patients.
The significant stock price increase is directly related to the positive clinical trial results, which are critical for the company's future prospects and investor confidence. The data suggests potential for the treatment to address unmet medical needs in HR-MDS and TP53m AML, which could lead to increased investor interest and valuation in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100